The medical devices industry continues to be a hotbed of innovation, with activity driven by increased need for homecare, preventative treatments, early diagnosis, reducing patient recovery times and improving outcomes, as well as a growing importance in technologies such as machine learning, augmented reality, 5G and digitalisation. In the last three years alone, there have been over 450,000 patents filed and granted in the medical devices industry. , according to GlobalData’s report on Innovation in Medical Devices: Bioresorbable stent coating.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
150+ innovations will shape the medical devices industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the medical devices industry using innovation intensity models built on over 550,000 patents, there are 150+ innovation areas that will shape the future of the industry.
Within the emerging innovation stage, neurostimulation therapy, smart physiotherapy devices, and real-time IR thermographic imaging are disruptive technologies that are in the early stages of application and should be tracked closely. Precision radiotherapy, electric atomisers, and bio-active prosthesis coating are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are bioresorbable stent coating and cryogenic tissue treatment, which are now well established in the industry.
Innovation S-curve for the medical devices industry
Bioresorbable stent coating is a key innovation area in the medical devices industry
Bioreabsorbable stents are typically made from polylactic acid which is the same material used in dissolvable sutures. These stents do not leave any metal body behind and hence, the possibility of late-stent thrombosis and restenosis decreases. Bioabsorbable stents help in improved drug delivery compared to metallic stents.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 220+ companies, spanning technology vendors, established medical devices companies, and up-and-coming start-ups engaged in the development and application of bioresorbable stent coating.
Key players in bioresorbable stent coating – a disruptive innovation in the medical devices industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to bioresorbable stent coating
Source: GlobalData Patent Analytics
Abbott Laboratories is one of the leading patent filers in the field of bioresorbable stent coating. Some other key patent filers in the field include Medtronic and Boston Scientific.
In terms of application diversity, Aveni leads the pack, followed by Abbott Laboratories and 3M. By means of geographic reach, Cardiatis holds the top position, followed by Johnson and Johnson and Baxter International in the second and third spots, respectively.
Improvements and advancements in stent-coating technologies, materials, and platforms have been incorporated into the latest generation of drug eluting stents (DES) that are developed with biodegradable polymer and polymer-free coatings, bioengineered surfaces, and novel antiproliferative drugs. The market entry of the next generation of DES with biodegradable polymer/polymer-free coatings will boost with the establishment of their safety, efficacy, and performance compared with the DES that are currently used in clinical practice.
To further understand the key themes and technologies disrupting the medical devices industry, access GlobalData’s latest thematic research report on Medical Devices.